Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
agreed. Thermofisher also acquired Affymetrix which used to be located 1.3 miles from Arrayit's headquarters in Sunnyvale. They do more genetics microarray products as opposed to Arrayit's protein microarrays but still the same scientific field.
very significant piece of due diligence here. I live near the center of bio-tech central (South San Francisco) and I see all the companies that are currently doing business with ARYC (with Thermofisher being one of the biggest).
BARCHART cheat sheet:
https://www.barchart.com/stocks/quotes/ARYC/opinion
In addition - The DOD would purchase these cards from Arrayit for uses such as this:
https://health.mil/News/Articles/2016/10/20/Years-of-blood-and-tissue-samples-helps-DoD-make-major-contribution-to-Cancer-Moonshot
https://health.mil/News/Gallery/Infographics/2016/08/03/Department-of-Defense-Serum-Repository
I guess there is a misunderstanding about what the sales/revenues are.
"completes 800 whole blood card production run"
To me that implies that Arrayit has created 800 blood cards for the DOD. It doesn't mention anything about processing the blood cards. I was a manufacturing engineer for years and we determine "production runs" as producing/creating product. I understand the cost of processing the blood cards for analysis and that would be hundreds more than the mere production. It really depends on whether the DOD simply purchased the cards or are asking Arrayit to do the processing as well. I would think the DOD has already purchased the machines to do their own analysis, but if not. Great - Arrayit gets to process 800 cards for the DOD
Arrayit Whole Blood Collection Cards to collect, sample and store whole human blood, 4 dotted circle 12.5 mm collection areas per card, compact (2.5 x 3.5”) dimensions, advanced high-purity collection matrix, impermeable collection area backing, barcode identifier, folding design for environmental protection, protein microarray and many other downstream applications, ready to use, 100 cards per package.
100 whole blood cards are sold at $502.00.
http://shop.arrayit.com/blood-card.aspx
So even just an 800 production run for the DOD would be a sale of $4016.00.
Thanks for the update, MikeCR. Been wanting to post but was busy
Tomorrow is the Case Management Conference between Iconic Holdings and Arrayit.
I agree. For being top executives in their company, they have fairly modest compensation:
http://www1.salary.com/ARRAYIT-CORP-Executive-Salaries.html
Just waiting for the release of the financials with the updated 2014, 2015, and 2016 data
cool. thanks. Have a good day
ARRAYIT CORPORATION (OTCMKTS:ARYC) had a decrease of 72.08% in short interest. ARYC’s SI was 28,000 shares in March as released by FINRA. Its down 72.08% from 100,300 shares previously. The stock increased 3.40% or $0.00017 on March 6, reaching $0.00517. About 2.42 million shares traded. Arrayit Corp (OTCMKTS:ARYC) has risen 638.57% since August 8, 2016 and is uptrending. It has outperformed by 629.29% the S&P500.
https://wolcottdaily.com/sunstone-hotel-investors-sho-forms-14-62-double-top-arrayit-corporation-aryc-shorts-decreased-by-72-08/
Agreed. It's why they asked the new financial auditors to correct the past 2 years reports as well as their current year.
Sweet!!
Thanks for the update, MikeCR. I'm hoping all goes well for ARYC for this lawsuit and this other one too:
https://roa.sdcourt.ca.gov/roa/faces/CaseSearch.xhtml
Enter the following case number: 37-2016-00026937
Don't use the Legacy Case Number. Just Select "37" and the year "2016" then "00026937"
More tidbits about Reuben Taub:
Page 61 from a book called "Making Dollars with Pennies"
https://books.google.com/books?id=NGvxfEfQOU8C&pg=PA61&lpg=PA61&dq=Reuben+G.+Taub&source=bl&ots=JVKZthIc_d&sig=j1ymW0AJ8H4piBfAAh1ePgzkHP4&hl=en&sa=X&ved=0ahUKEwiJzrOTz7DSAhXIgVQKHVasCHoQ6AEIQzAH#v=onepage&q=Reuben%20G.%20Taub&f=false
Great post! Thanks for the info and link
Here's the latest:
https://roa.sdcourt.ca.gov/roa/faces/CaseSearch.xhtml
Enter the following case number: 37-2016-00026937
Don't use the Legacy Case Number. Just Select "37" and the year "2016" then "00026937"
The science behind ARYC is real. The products are real. Here is an example use of Protein Microarray:
The researchers, led by Zdenek Hel, Ph.D., associate professor in the UAB Department of Pathology, used a technique called protein microarray analysis. A total of 39 different protein antigens from gut bacteria -- antigens that are known to elicit antibody immune responses in humans against those antigens -- were used to bind antibodies from gut wash fluid. A variety of food antigen proteins were also used to bind antibodies. Researchers then could test what types of antibodies were produced in HIV-1-positive and HIV-1-negative subjects.
https://www.sciencedaily.com/releases/2017/01/170126144613.htm
Parkinson’s Disease Therapeutics
Several companies are developing small molecule and protein therapeutics for Parkinsons’ Disease. The Arrayit PDx™ Test provides a molecular assay for benchmarking and optimizing PD medicines and targeting treatment to bona fide PD patients.
FDA Approval
Arrayit PDx™ Pre-Symptomatic Test for Parkinson’s Disease will be submitted to the United Sates Food and Drug Administration (FDA) as a 510(k) submission in the near future.
I wouldn't put too much weight on that link. The fact that it says:
Public, Subsidiary of Genentech, Inc. >, OTCBB, ARYC
is already a clue that it's not reliable. Genentech is definitely not Arrayit's holding company.
For those of you who actually care about the science behind ARYC:
http://bmcbiotechnol.biomedcentral.com/articles/10.1186/1472-6750-10-12
Long story short:
Protein microarray as an emerging technology has many advantages over the traditional ELISA (Enzyme-Linked Immuno-Sorbant Assay) method. It is a versatile, miniature and high-throughput platform that can be adapted for a variety of screening uses. Protein microarrays are already widely used to perform high though-put drug screens, to study protein-protein interactions, and have great potential for disease diagnosis
Just wanted to say thank you for making this call. Rene is such a pleasure to speak with
Next levels up looking good so far:
https://www.barchart.com/stocks/quotes/ARYC/cheat-sheet
Buychart Opinion:
https://www.barchart.com/stocks/quotes/ARYC/opinion
"This inherent power of position enables the MMs to move the markets at any time up or down. As a result, the only way to draw them out of their favorable position is going long. Now this does not mean just any company but to effectively nail the MMs, Longs must find the great company on the floor and accumulate long before the MM tactics and games begin."
Good read, thanks
Just called and spoke to Rene Schena (CEO) and yes she answered the phone. I asked her about the upcoming financials and she ensured me that they are "diligently working" to get the updates out as soon as possible with their new auditing firm. They apparently are still working out the numbers from their old filings (2014 and 2015) so they want to make sure those are correct as well but she seemed very very kind. I encourage anyone to call 408-744-1331 if you want to speak to her yourself.
Thanks
List of Quidel's acquisitions:
Acquisitions
In 2013, the company acquired BioHelix Corporation (BioHelix), which was established in 2004,[5] and will pay $10 million to the BioHelix shareholders.
In 2010, the Company acquired Diagnostic Hybrids, Inc. a privately held in vitro diagnostic company.
In 2000, the Company acquired Litmus Concepts, Inc., a privately held in vitro diagnostic company.
In 1999, the Company acquired Metra Biosystems, Inc.to participate in bone health assessment.
Yeah that one is old I think. I forgot where I got the other one. I think it's from one of the 8-ks. I haven't gotten any replies yet though
I tried this one
investorinfo@arrayit.com
Is that what you used?
I'm not worried about the short term sellers and profit takers. All that matters are the real products, and the mergers and acquisitions. The important biotech giant buyers will determine the buyout share price in the end. I just want to make sure I have a significant amount when that happens.
Here's a reminder of what happened in this space last year:
http://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2016/Thermo-Fisher-Scientific-Completes-Acquisition-of-Affymetrix-Following-Approval-of-Transaction-by-Affymetrix-Stockholders/default.aspx
Great post! Indeed very relevant with ARYC's technology
As stated in the report, the prime players operating in the market are Illumina, Inc., Affymetrix, Inc., Molecular Devices, LLC, Bio-Rad Laboratories, Agilent Technologies, Inc., Thermo Fischer Scientific, Sigma-Aldrich Corporation, and ArrayIt Corporation, among others
Agreed!
A new Transparency Market Research report states that the global array instruments market stood at US$0.87 bn in 2014 and is predicted to reach US$1.12 bn in 2020. It is predicted to expand at a CAGR of 4.30% from 2014 to 2020.
http://www.openpr.com/news/399062/Array-Instruments-Market-Global-Industry-Analysis-2014-2020.html
I'm selling off cannabis and alternative energy stocks to get more $ARYC. There's just way too much legislation and efforts to expand biotech for the sake of finding cures to ignore this stock